We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
bluebird bio (BLUE) Looks Good: Stock Adds 8.5% in Session
Read MoreHide Full Article
bluebird bio, Inc. (BLUE - Free Report) was a big mover last session, as the company saw its shares rise almost 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of$75.35 –$90.45 in the past one-month time frame.
The upside is likely to have been driven by the company’s recently released updated results from an ongoing early-stage clinical trial in relapsed/refractory multiple myeloma.
The company has seen seven positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past month, suggesting that more solid trading could be ahead for Intercept Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Bluebird bio currently has a Zacks Rank #3 (Hold) while its Earnings ESPis positive.
Is BLUE going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
bluebird bio (BLUE) Looks Good: Stock Adds 8.5% in Session
bluebird bio, Inc. (BLUE - Free Report) was a big mover last session, as the company saw its shares rise almost 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of$75.35 –$90.45 in the past one-month time frame.
The upside is likely to have been driven by the company’s recently released updated results from an ongoing early-stage clinical trial in relapsed/refractory multiple myeloma.
The company has seen seven positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past month, suggesting that more solid trading could be ahead for Intercept Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Bluebird bio currently has a Zacks Rank #3 (Hold) while its Earnings ESPis positive.
bluebird bio, Inc. Price and Consensus
bluebird bio, Inc. Price and Consensus | bluebird bio, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Geneticsindustry is VIVUS, Inc.(VVUS), which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is BLUE going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>